Shots:
- CuraTeQ Biologics, a subsidiary of Aurobindo Pharma, reported EC’s approval of Dazublys, its trastuzumab biosimilar following the CHMP’s recommendation in Apr 2025
- The approval was based on its demonstrated similarity to Herceptin in PK, PD, efficacy, safety, and immunogenicity
- Dazublys is approved for HER2-positive breast and gastric cancers, and expanding access to treatment across the EU
Ref: CuraTeQ | Image: CuraTeQ | Press Release
Related News:- CuraTeQ Biologics Receives CHMP’s Positive Opinion for Dazublys (Biosimilar, Herceptin)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
